Your browser doesn't support javascript.
loading
Zinc oxide nanoparticles: a 90-day repeated-dose dermal toxicity study in rats.
Ryu, Hwa Jung; Seo, Mu Yeb; Jung, Sung Kyu; Maeng, Eun Ho; Lee, Seung-Young; Jang, Dong-Hyouk; Lee, Taek-Jin; Jo, Ki-Yeon; Kim, Yu-Ri; Cho, Kyu-Bong; Kim, Meyoung-Kon; Lee, Beom Jun; Son, Sang Wook.
Affiliation
  • Ryu HJ; Department of Dermatology, Korea University College of Medicine, Seoul.
  • Seo MY; Korea Testing and Research Institute, Gyunggido, Republic of Korea.
  • Jung SK; Department of Dermatology, Korea University College of Medicine, Seoul.
  • Maeng EH; Korea Testing and Research Institute, Gyunggido, Republic of Korea.
  • Lee SY; Korea Testing and Research Institute, Gyunggido, Republic of Korea.
  • Jang DH; Korea Testing and Research Institute, Gyunggido, Republic of Korea.
  • Lee TJ; Korea Testing and Research Institute, Gyunggido, Republic of Korea.
  • Jo KY; Korea Testing and Research Institute, Gyunggido, Republic of Korea.
  • Kim YR; Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, Republic of Korea.
  • Cho KB; Department of Clinical Laboratory Science, Shinheung College, Uijeongbu, Republic of Korea.
  • Kim MK; Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, Republic of Korea.
  • Lee BJ; College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea.
  • Son SW; Department of Dermatology, Korea University College of Medicine, Seoul.
Int J Nanomedicine ; 9 Suppl 2: 137-44, 2014.
Article in En | MEDLINE | ID: mdl-25565832
ABSTRACT
Zinc oxide (ZnO) works as a long-lasting, broad-spectrum physical sunblock, and can prevent skin cancer, sunburn, and photoaging. Nanosized ZnO particles are used often in sunscreens due to consumer preference over larger sizes, which appear opaque when dermally applied. Although the US Food and Drug Administration approved the use of nanoparticles (NPs) in sunscreens in 1999, there are ongoing safety concerns. The aim of this study was to evaluate the subchronic toxicity of ZnO NPs after dermal application according to the Organization for Economic Cooperation and Development Test Guidelines 411 using Good Laboratory Practice. Sprague Dawley rats were randomly divided into eight (one control, one vehicle control, three experimental, and three recovery) groups. Different concentrations of ZnO NPs were dermally applied to the rats in the experimental groups for 90 days. Clinical observations as well as weight and food consumption were measured and recorded daily. Hematology and biochemistry parameters were determined. Gross pathologic and histopathologic examinations were performed on selected tissues from all animals. Analyses of tissue were undertaken to determine target organ tissue distribution. There was no increased mortality in the experimental group. Although there was dose-dependent irritation at the site of application, there were no abnormal findings related to ZnO NPs in other organs. Increased concentrations of ZnO in the liver, small intestine, large intestine, and feces were thought to result from oral ingestion of ZnO NPs via licking. Penetration of ZnO NPs through the skin seemed to be limited via the dermal route. This study demonstrates that there was no observed adverse effect of ZnO NPs up to 1,000 mg/kg body weight when they are applied dermally.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Zinc Oxide / Nanoparticles Type of study: Guideline Limits: Animals Language: En Journal: Int J Nanomedicine Year: 2014 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Zinc Oxide / Nanoparticles Type of study: Guideline Limits: Animals Language: En Journal: Int J Nanomedicine Year: 2014 Document type: Article